Nightingale Health Plc, Press release, 17 August 2023 at 9:55 a.m. (EEST)

Nightingale Health Plc (“Nightingale Health”), a technology company promoting preventative health with its proprietary health risk detection platform, has rolled out a remote blood collection kit for its medical research and clinical trial customers. This launch follows the company’s acquisition of the worldwide license and rights to the Velvet™ self-collection device in January 2023.

Nightingale Kit and its self-collection device allow study participants to draw their own blood sample from a finger-prick. This creates substantial flexibility and enables study designs that have previously been constrained by geographical and logistic limitations. Additionally, since Nightingale Health provides both sample collection and sample analysis, remote blood collection can be incorporated into studies in a seamless, cost-efficient way.

Nightingale Kit for remote blood collection is available for medical research and clinical trials immediately. The biomarkers analyzed for research use from the dry blood sample taken with Nightingale Kit cover a wide range of biological functions, including lipids (e.g., LDL cholesterol, HDL cholesterol, triglycerides, ApoA1, and ApoB), insulin sensitivity (amino acids), dietary intake (e.g., omega-3 and omega-6 fatty acids), chronic inflammation (GlycA), fluid balance (e.g., albumin), and kidney function (e.g., creatinine).

More information of the new offering is available at the company’s website:

For further information, please contact:

Teemu Suna, CEO

About Nightingale Health

Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 25 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 450 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: